Evidence map›Paper›PMID 36443570›Full record

ArticleRheumatology and therapy2023

Sequential Tocilizumab and Tofacitinib Treatment for Systemic Juvenile Idiopathic Arthritis: a Case Report.

Ye Zhang, Jinli Ru, Jinxiu Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ye ZhangDepartment of General Medicine, The Second Hospital of Shanxi Medical University (The Second Clinical Medical College of Shanxi Medical University, Shanxi Red Cross Hospital), No. 382, Wuyi Road, Taiyuan, 030001, Shanxi, China.
Jinli RuDepartment of General Medicine, The Second Hospital of Shanxi Medical University (The Second Clinical Medical College of Shanxi Medical University, Shanxi Red Cross Hospital), No. 382, Wuyi Road, Taiyuan, 030001, Shanxi, China. rujinli@163.com.ORCID http://orcid.org/0000-0003-3954-1819
Jinxiu ZhangDepartment of General Medicine, The Second Hospital of Shanxi Medical University (The Second Clinical Medical College of Shanxi Medical University, Shanxi Red Cross Hospital), No. 382, Wuyi Road, Taiyuan, 030001, Shanxi, China.
Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic juvenile idiopathic arthritis (sJIA) is a complex and difficult to cure condition with high disability and mortality rates. Herein, we report the case of a patient with sJIA who was treated with sequential tocilizumab (TCZ) and tofacitinib treatment. The patient was a 4-year-old girl hospitalised with fever accompanied by multiple joint swelling and pain in June 2020. Laboratory tests revealed a white blood cell count of 15.3 × 10

Indexed as

Sequential treatmentSystemic juvenile idiopathic arthritisTocilizumabTofacitinib

Identifiers

PMID36443570
PMCPMC9931954
OpenAlexW4310464933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.